Exploring the Impact of Airway Microbiome on Asthma Morbidity: A Focus on the "Constructing a 'Eubiosis Reinstatement Therapy' for Asthma-CURE" Project.
Asthma
Bacteriophages
CURE concept
Microbiome
Virome
Virus
Journal
Pulmonary therapy
ISSN: 2364-1746
Titre abrégé: Pulm Ther
Pays: United States
ID NLM: 101687144
Informations de publication
Date de publication:
30 May 2024
30 May 2024
Historique:
received:
26
02
2024
accepted:
02
05
2024
medline:
30
5
2024
pubmed:
30
5
2024
entrez:
30
5
2024
Statut:
aheadofprint
Résumé
The asthma pandemic imposes a huge burden on patients and health systems in both developed and developing countries. Despite available treatments, symptom control is generally suboptimal, and hospitalizations and deaths remain at unacceptably high levels. A pivotal aspect of asthma that warrants further exploration is the influence of the respiratory microbiome and virome in modulating disease activity. A plethora of studies report that the respiratory microbiome is characteristically dysbiotic in asthma. In addition, our data suggest that dysbiosis is also observed on the respiratory virome, partly characterized by the reduced abundance of bacteriophages (phages). Even though phages can naturally infect and control their bacterial prey, phage therapy has been grossly neglected in the Western world, although more recently it is more widely used as a novel tool against bacterial infections. However, it has never been used for tackling microbiome dysbiosis in human non-communicable diseases. This review provides an up-to-date understanding of the microbiome and virome's role within the airways in relation to asthma morbidity. It also advances the rationale and hypothesis for the CURE project. Specifically, the CURE project suggests that managing the respiratory microbiome through phage therapy is viable and may result in restoring eubiosis within the asthmatic airway. This entails controlling immune dysregulation and the clinical manifestation of the disease. To accomplish this goal, it is crucial to predict the effects of introducing specific phage mixtures into the intricate ecology of the airways and devise suitable interventions.
Identifiants
pubmed: 38814533
doi: 10.1007/s41030-024-00261-3
pii: 10.1007/s41030-024-00261-3
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : HORIZON EUROPE Framework Programme
ID : 767015
Investigateurs
Grigoris Kaltsas
(G)
Evangelia Lebessi
(E)
Anastassios Doudoulakakis
(A)
Stella Taka
(S)
Panagiota Tzani Tzanopoulou
(PT)
Evangelia Legaki
(E)
Rena Stergiou
(R)
David Robertson
(D)
Tucker Gilman
(T)
Mark Muldoon
(M)
Avraam Tapinos
(A)
Chuan Fu Yap
(CF)
George Gkimpas
(G)
Joe Busby
(J)
Mubeccel Akdis
(M)
Cezmi Akdis
(C)
Anna Globinska
(A)
Ramazan Rozumbetov
(R)
Vangelis Andreakos
(V)
Ioanna Galani
(I)
Mikaela Koutrouli
(M)
Vaso Triantafullia
(V)
Hannah Wanstall
(H)
Maria Papadaki
(M)
Marek Kowalski
(M)
Aleksandra Wardzyńska
(A)
Maciej Chałubiński
(M)
Nina Chanishvili
(N)
Elene Kakabadze
(E)
Marina Goderdzishvili
(M)
Valeria Ramiconi
(V)
Isabel Proano
(I)
Sofia Romagosa
(S)
Christos Ilioudis
(C)
Athina Thanopoulou
(A)
Dimitris Raptis
(D)
Informations de copyright
© 2024. The Author(s).
Références
Papadopoulos NG, Miligkos M, Xepapadaki P. A current perspective of allergic asthma: From mechanisms to management. Handb Exp Pharmacol. 2022;268:69–93.
pubmed: 34085124
doi: 10.1007/164_2021_483
Global Initiative for Asthma (GINA) report. Global strategy for asthma management and prevention 2023 update.
Papadopoulos NG, Christodoulou I, Rohde G, et al. Viruses and bacteria in acute asthma exacerbations—a GA(2) LEN-DARE systematic review. Allergy. 2011;66(4):458–68.
pubmed: 21087215
doi: 10.1111/j.1398-9995.2010.02505.x
Contoli M, Message SD, Laza-Stanca V, et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med. 2006;12(9):1023–6.
pubmed: 16906156
doi: 10.1038/nm1462
Teo SM, Mok D, Pham K, et al. The infant nasopharyngeal microbiome impacts severity of lower respiratory infection and risk of asthma development. Cell Host Microbe. 2015;17(5):704–15.
pubmed: 25865368
pmcid: 4433433
doi: 10.1016/j.chom.2015.03.008
Lee-Sarwar KA, Kelly RS, Lasky-Su J, et al. Integrative analysis of the intestinal metabolome of childhood asthma. J Allergy Clin Immunol. 2019;144(2):442–54.
pubmed: 30914378
pmcid: 6688902
doi: 10.1016/j.jaci.2019.02.032
Castro-Nallar E, Shen Y, Freishtat RJ, et al. Integrating microbial and host transcriptomics to characterize asthma-associated microbial communities. BMC Med Genom. 2015;8:50.
doi: 10.1186/s12920-015-0121-1
Bai GH, Lin SC, Hsu YH, Chen SY. The human virome: viral metagenomics, relations with human diseases, and therapeutic applications. Viruses. 2022;14(2):278.
pubmed: 35215871
pmcid: 8876576
doi: 10.3390/v14020278
Leal Rodriguez C, Shah SA, Rasmussen MA, et al. The infant gut virome is associated with preschool asthma risk independently of bacteria. Nat Med. 2024;30(1):138–48.
pubmed: 38102298
doi: 10.1038/s41591-023-02685-x
Spyridon M, Bede C, Paraskevi X, et al. Bacteriophage deficiency characterizes respiratory virome dysbiosis in childhood asthma. BioRxiv. 2020.
Sweere JM, Van Belleghem JD, Ishak H, et al. Bacteriophage trigger antiviral immunity and prevent clearance of bacterial infection. Science. 2019. https://doi.org/10.1126/science.aat9691 .
doi: 10.1126/science.aat9691
pubmed: 30923196
pmcid: 6656896
Choi S, Sohn KH, Jung JW, et al. Lung virome: new potential biomarkers for asthma severity and exacerbation. J Allergy Clin Immunol. 2021;148(4):1007–15 (e9).
pubmed: 33757721
doi: 10.1016/j.jaci.2021.03.017
Chevallereau A, Pons BJ, van Houte S, Westra ER. Interactions between bacterial and phage communities in natural environments. Nat Rev Microbiol. 2022;20(1):49–62.
pubmed: 34373631
doi: 10.1038/s41579-021-00602-y
Strathdee SA, Hatfull GF, Mutalik VK, Schooley RT. Phage therapy: From biological mechanisms to future directions. Cell. 2023;186(1):17–31.
pubmed: 36608652
pmcid: 9827498
doi: 10.1016/j.cell.2022.11.017
Valdes AM, Walter J, Segal E, Spector TD. Role of the gut microbiota in nutrition and health. BMJ. 2018;361: k2179.
pubmed: 29899036
pmcid: 6000740
doi: 10.1136/bmj.k2179
Hilty M, Burke C, Pedro H, et al. Disordered microbial communities in asthmatic airways. PLoS One. 2010;5(1): e8578.
pubmed: 20052417
pmcid: 2798952
doi: 10.1371/journal.pone.0008578
Man WH, de Steenhuijsen Piters WA, Bogaert D. The microbiota of the respiratory tract: gatekeeper to respiratory health. Nat Rev Microbiol. 2017;15(5):259–70.
pubmed: 28316330
pmcid: 7097736
doi: 10.1038/nrmicro.2017.14
Mason RD, Welles HC, Adams C, et al. Targeted isolation of antibodies directed against major sites of SIV Env vulnerability. PLoS Pathog. 2016;12(4): e1005537.
pubmed: 27064278
pmcid: 4827850
doi: 10.1371/journal.ppat.1005537
Dickson RP, Erb-Downward JR, Freeman CM, et al. Spatial variation in the healthy human lung microbiome and the adapted island model of lung biogeography. Ann Am Thorac Soc. 2015;12(6):821–30.
pubmed: 25803243
pmcid: 4590020
doi: 10.1513/AnnalsATS.201501-029OC
Zhou A, Lei Y, Tang L, et al. Gut microbiota: the emerging link to lung homeostasis and disease. J Bacteriol. 2021;203(4):10–1128.
doi: 10.1128/JB.00454-20
Kang HM, Kang JH. Effects of nasopharyngeal microbiota in respiratory infections and allergies. Clin Exp Pediatr. 2021;64(11):543–51.
pubmed: 33872488
pmcid: 8566799
doi: 10.3345/cep.2020.01452
Liu T, Lin CH, Chen YL, et al. Nasal microbiome change during and after exacerbation in asthmatic children. Front Microbiol. 2021;12: 833726.
pubmed: 35310400
doi: 10.3389/fmicb.2021.833726
Huang YJ, Nelson CE, Brodie EL, et al. Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma. J Allergy Clin Immunol. 2011;127(2):372–81 (e1-3).
pubmed: 21194740
doi: 10.1016/j.jaci.2010.10.048
Lynch SV. The lung microbiome and airway disease. Ann Am Thorac Soc. 2016;13(Suppl 2):S462–5.
pubmed: 28005424
pmcid: 5291470
doi: 10.1513/AnnalsATS.201605-356AW
Huang C, Ni Y, Du W, Shi G. Effect of inhaled corticosteroids on microbiome and microbial correlations in asthma over a 9-month period. Clin Transl Sci. 2022;15:1723–36.
pubmed: 35514165
pmcid: 9283747
doi: 10.1111/cts.13288
McCauley K, Durack J, Valladares R, et al. Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma. J Allergy Clin Immunol. 2019;144(5):1187–97.
pubmed: 31201890
pmcid: 6842413
doi: 10.1016/j.jaci.2019.05.035
Mahdavinia M, Fyolek JP, Jiang J, et al. Gut microbiome is associated with asthma and race in children with food allergy. J Allergy Clin Immunol. 2023;152(6):1541–9 (e1).
pubmed: 37714436
doi: 10.1016/j.jaci.2023.07.024
Kozik AJ, Begley LA, Lugogo N, et al. Airway microbiota and immune mediator relationships differ in obesity and asthma. J Allergy Clin Immunol. 2023;151(4):931–42.
pubmed: 36572355
doi: 10.1016/j.jaci.2022.11.024
Mageiros L, Megremis S, Papadopoulos NG. The virome in allergy and asthma: a nascent, ineffable player. J Allergy Clin Immunol. 2023;152(6):1347–51.
pubmed: 37778473
doi: 10.1016/j.jaci.2023.09.022
Dodi G, Attanasi M, Di Filippo P, Di Pillo S, Chiarelli F. Virome in the lungs: the role of anelloviruses in childhood respiratory diseases. Microorganisms. 2021;9(7):1357.
pubmed: 34201449
pmcid: 8307813
doi: 10.3390/microorganisms9071357
Weinbauer MG, Rassoulzadegan F. Are viruses driving microbial diversification and diversity? Environ Microbiol. 2004;6(1):1–11.
pubmed: 14686936
doi: 10.1046/j.1462-2920.2003.00539.x
Koskella B, Brockhurst MA. Bacteria-phage coevolution as a driver of ecological and evolutionary processes in microbial communities. FEMS Microbiol Rev. 2014;38(5):916–31.
pubmed: 24617569
doi: 10.1111/1574-6976.12072
Tzani-Tzanopoulou P, Skliros D, Megremis S, et al. Interactions of bacteriophages and bacteria at the airway mucosa: new insights into the pathophysiology of asthma. Front Allergy. 2020;1: 617240.
pubmed: 35386933
doi: 10.3389/falgy.2020.617240
Wylie KM, Mihindukulasuriya KA, Zhou Y, Sodergren E, Storch GA, Weinstock GM. Metagenomic analysis of double-stranded DNA viruses in healthy adults. BMC Biol. 2014;12:71.
pubmed: 25212266
pmcid: 4177058
doi: 10.1186/s12915-014-0071-7
Mitchell AB, Oliver BG, Glanville AR. Translational aspects of the human respiratory virome. Am J Respir Crit Care Med. 2016;194(12):1458–64.
pubmed: 27653942
doi: 10.1164/rccm.201606-1278CI
Xepapadaki P, Papadopoulos NG. Childhood asthma and infection: virus-induced exacerbations as determinants and modifiers. Eur Respir J. 2010;36(2):438–45.
pubmed: 20675781
doi: 10.1183/09031936.00149009
Freer G, Maggi F, Pifferi M, Di Cicco ME, Peroni DG, Pistello M. The virome and its major component, anellovirus, a convoluted system molding human immune defenses and possibly affecting the development of asthma and respiratory diseases in childhood. Front Microbiol. 2018;9:686.
pubmed: 29692764
pmcid: 5902699
doi: 10.3389/fmicb.2018.00686
Romero-Espinoza JA, Moreno-Valencia Y, Coronel-Tellez RH, et al. Virome and bacteriome characterization of children with pneumonia and asthma in Mexico City during winter seasons 2014 and 2015. PLoS One. 2018;13(2): e0192878.
pubmed: 29447223
pmcid: 5813968
doi: 10.1371/journal.pone.0192878
Megremis S, Constantinides B, Xepapadaki P, et al. Respiratory eukaryotic virome expansion and bacteriophage deficiency characterize childhood asthma. Sci Rep. 2023;13(1):8319.
pubmed: 37221274
pmcid: 10205716
doi: 10.1038/s41598-023-34730-7
Xepapadaki P, Bachert C, Finotto S, et al. Contribution of repeated infections in asthma persistence from preschool to school age: Design and characteristics of the PreDicta cohort. Pediatr Allergy Immunol. 2018;29(4):383–93.
pubmed: 29512854
doi: 10.1111/pai.12881
Belkaid Y, Naik S. Compartmentalized and systemic control of tissue immunity by commensals. Nat Immunol. 2013;14(7):646–53.
pubmed: 23778791
doi: 10.1038/ni.2604
Rovira Rubio J, Megremis S, Pasioti M, et al. Respiratory virome profiles reflect antiviral immune responses. Allergy. 2023;78(5):1258–68.
pubmed: 36595290
doi: 10.1111/all.15634
Duerkop BA, Hooper LV. Resident viruses and their interactions with the immune system. Nat Immunol. 2013;14(7):654–9.
pubmed: 23778792
pmcid: 3760236
doi: 10.1038/ni.2614
Federici S, Nobs SP, Elinav E. Phages and their potential to modulate the microbiome and immunity. Cell Mol Immunol. 2021;18(4):889–904.
pubmed: 32901128
doi: 10.1038/s41423-020-00532-4
Jonczyk-Matysiak E, Weber-Dabrowska B, Owczarek B, et al. Phage-phagocyte interactions and their implications for phage application as therapeutics. Viruses. 2017;9(6):150.
pubmed: 28613272
pmcid: 5489797
doi: 10.3390/v9060150
Looi K, Buckley AG, Rigby PJ, et al. Effects of human rhinovirus on epithelial barrier integrity and function in children with asthma. Clin Exp Allergy. 2018;48(5):513–24.
pubmed: 29350877
doi: 10.1111/cea.13097
Celebi Sozener Z, Cevhertas L, Nadeau K, Akdis M, Akdis CA. Environmental factors in epithelial barrier dysfunction. J Allergy Clin Immunol. 2020;145(6):1517–28.
pubmed: 32507229
doi: 10.1016/j.jaci.2020.04.024
Leung CYJ, Weitz JS. Modeling the synergistic elimination of bacteria by phage and the innate immune system. J Theor Biol. 2017;429:241–52.
pubmed: 28668337
doi: 10.1016/j.jtbi.2017.06.037
Tzani-Tzanopoulou P, Rozumbetov R, Taka S, et al. Development of an in vitro homeostasis model between airway epithelial cells, bacteria and bacteriophages: a time-lapsed observation of cell viability and inflammatory response. J Gen Virol. 2022. https://doi.org/10.1099/jgv.0.001819 .
doi: 10.1099/jgv.0.001819
pubmed: 36748697
Carr TF, Alkatib R, Kraft M. Microbiome in mechanisms of asthma. Clin Chest Med. 2019;40(1):87–96.
pubmed: 30691719
doi: 10.1016/j.ccm.2018.10.006
Venkataraman A, Bassis CM, Beck JM, et al. Application of a neutral community model to assess structuring of the human lung microbiome. MBio. 2015. https://doi.org/10.1128/mBio.02284-14 .
doi: 10.1128/mBio.02284-14
pubmed: 25604788
pmcid: 4324308
Green BJ, Wiriyachaiporn S, Grainge C, et al. Potentially pathogenic airway bacteria and neutrophilic inflammation in treatment resistant severe asthma. PLoS One. 2014;9(6): e100645.
pubmed: 24955983
pmcid: 4067344
doi: 10.1371/journal.pone.0100645
Shade A. Diversity is the question, not the answer. ISME J. 2017;11(1):1–6.
pubmed: 27636395
doi: 10.1038/ismej.2016.118
Durack J, Lynch SV, Nariya S, et al. Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment. J Allergy Clin Immunol. 2017;140(1):63–75.
pubmed: 27838347
doi: 10.1016/j.jaci.2016.08.055
Hufnagl K, Pali-Scholl I, Roth-Walter F, Jensen-Jarolim E. Dysbiosis of the gut and lung microbiome has a role in asthma. Semin Immunopathol. 2020;42(1):75–93.
pubmed: 32072252
pmcid: 7066092
doi: 10.1007/s00281-019-00775-y
Zheng J, Wu Q, Zou Y, Wang M, He L, Guo S. Respiratory microbiota profiles associated with the progression from airway inflammation to remodeling in mice with OVA-induced asthma. Front Microbiol. 2021;12: 723152.
pubmed: 34526979
pmcid: 8435892
doi: 10.3389/fmicb.2021.723152
Papadopoulos NG, Barnes P, Canonica GW, et al. The evolving algorithm of biological selection in severe asthma. Allergy. 2020;75(7):1555–63.
pubmed: 32124991
doi: 10.1111/all.14256
Xepapadaki P, Adachi Y, Pozo Beltran CF, et al. Utility of biomarkers in the diagnosis and monitoring of asthmatic children. World Allergy Organ J. 2023;16(1): 100727.
pubmed: 36601259
doi: 10.1016/j.waojou.2022.100727
Kutter E, Sulakvelidze A. Bacteriophages. Biology and Applications; 2004.
Onsea J, Uyttebroek S, Chen B, et al. Bacteriophage therapy for difficult-to-treat infections: the implementation of a Multidisciplinary Phage Task Force (The PHAGEFORCE Study Protocol). Viruses. 2021;13(8):1543.
pubmed: 34452408
pmcid: 8402896
doi: 10.3390/v13081543
Chanishvili N. Bacteriophages as therapeutic and prophylactic means: summary of the Soviet and post-Soviet experiences. Curr Drug Deliv. 2016;13(3):309–23.
pubmed: 27090515
doi: 10.2174/156720181303160520193946
Pirnay JP, Blasdel BG, Bretaudeau L, et al. Quality and safety requirements for sustainable phage therapy products. Pharm Res. 2015;32(7):2173–9.
pubmed: 25585954
pmcid: 4452253
doi: 10.1007/s11095-014-1617-7
Dicks LMT, Vermeulen W. Bacteriophage-host interactions and the therapeutic potential of bacteriophages. Viruses. 2024;16(3):478.
pubmed: 38543843
pmcid: 10975011
doi: 10.3390/v16030478
https://www.ema.europa.eu/en/human-regulatory-overview/public-health-threats/antimicrobial-resistance/antimicrobial-resistance-human-medicine .
Pelfrene E, Willebrand E, Cavaleiro Sanches A, Sebris Z, Cavaleri M. Bacteriophage therapy: a regulatory perspective. J Antimicrob Chemother. 2016;71(8):2071–4.
pubmed: 27068400
doi: 10.1093/jac/dkw083
Verbeken G, Pirnay JP, Lavigne R, et al. Call for a dedicated European legal framework for bacteriophage therapy. Arch Immunol Ther Exp (Warsz). 2014;62(2):117–29.
pubmed: 24500660
doi: 10.1007/s00005-014-0269-y
Jault P, Leclerc T, Jennes S, et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infect Dis. 2019;19(1):35–45.
pubmed: 30292481
doi: 10.1016/S1473-3099(18)30482-1
Uyttebroek S, Chen B, Onsea J, et al. Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review. Lancet Infect Dis. 2022;22(8):e208–20.
pubmed: 35248167
doi: 10.1016/S1473-3099(21)00612-5
Weber-Dabrowska B, Jonczyk-Matysiak E, Zaczek M, Lobocka M, Lusiak-Szelachowska M, Gorski A. Bacteriophage procurement for therapeutic purposes. Front Microbiol. 2016;7:1177.
pubmed: 27570518
pmcid: 4981656
Ross A, Ward S, Hyman P. More is better: selecting for broad host range bacteriophages. Front Microbiol. 2016;7:1352.
pubmed: 27660623
pmcid: 5014875
doi: 10.3389/fmicb.2016.01352
Zelasko S, Gorski A, Dabrowska K. Delivering phage therapy per os: benefits and barriers. Expert Rev Anti Infect Ther. 2017;15(2):167–79.
pubmed: 27885865
doi: 10.1080/14787210.2017.1265447
Charlson ES, Bittinger K, Haas AR, et al. Topographical continuity of bacterial populations in the healthy human respiratory tract. Am J Respir Crit Care Med. 2011;184(8):957–63.
pubmed: 21680950
pmcid: 3208663
doi: 10.1164/rccm.201104-0655OC
Boutin S, Graeber SY, Weitnauer M, et al. Comparison of microbiomes from different niches of upper and lower airways in children and adolescents with cystic fibrosis. PLoS One. 2015;10(1): e0116029.
pubmed: 25629612
pmcid: 4309611
doi: 10.1371/journal.pone.0116029
Huffnagle GB, Dickson RP, Lukacs NW. The respiratory tract microbiome and lung inflammation: a two-way street. Mucosal Immunol. 2017;10(2):299–306.
pubmed: 27966551
doi: 10.1038/mi.2016.108
Jover LF, Romberg J, Weitz JS. Inferring phage-bacteria infection networks from time-series data. R Soc Open Sci. 2016;3(11): 160654.
pubmed: 28018655
pmcid: 5180153
doi: 10.1098/rsos.160654